ProCE Banner Activity

How New Data May Change Myeloma Care in 2018 and Beyond

Clinical Thought
New data from ASH 2017 raise many questions regarding how these new approaches will fit into the current treatment paradigm for patients with myeloma.

Released: January 29, 2018

Expiration: January 28, 2019

No longer available for credit.

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Celgene

Takeda Oncology

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received consulting fees from AbbVie, Celgene, Janssen, Merck, and Takeda and funds for research support from AbbVie, Celgene, Janssen, Merck, Roche, Sanofi, and Takeda.